#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization

International Bureau



# 

# (43) International Publication Date 24 April 2008 (24.04.2008)

# (10) International Publication Number WO 2008/047241 A3

(51) International Patent Classification:

 C07K 14/575 (2006.01)
 A61P 9/00 (2006.01)

 A61K 47/48 (2006.01)
 A61P 9/02 (2006.01)

 A61K 9/08 (2006.01)
 C07K 1/107 (2006.01)

 A61P 21/06 (2006.01)
 C07K 19/00 (2006.01)

 A61P 25/00 (2006.01)
 C07K 14/765 (2006.01)

**A61P 3/04** (2006.01)

(21) International Application Number:

PCT/IB2007/004156

(22) International Filing Date:

16 October 2007 (16.10.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/852,443 16 October 2006 (16.10.2006) US 60/967,281 30 August 2007 (30.08.2007) US

- (71) Applicant (for all designated States except US): CON-JUCHEM BIOTECHNOLOGIES INC.; 225, President-Kennedy Avenue, Third Floor, Suite 3950, Montreal, QC H2X 3Y8 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ULICH, Thomas, R. [US/US]; 426 West 58th Street, Apt. 3B, New York, NY 10019 (US). ESTRADIER, JEAN-PHILIPPE [CA/ CA]; 225, President-kennedy Avenue, Third Floor, Suite


- 3950, Montreal, QC (CA). **THIBAUDEAU, KAREN** [CA/CA]; 225, President-kennedy Avenue, Third Floor, Suite 3950, Rosemere, QC (CA).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

— with international search report (Art. 21(3))

[Continued on next page]

#### (54) Title: MODIFIED CORTICOTROPIN RELEASING FACTOR PEPTIDES AND USES THEREOF



2009% NeCl 2009 Seq ID No. 92 (hUch ii) 2009 Seq ID No. 82 2009 Seq ID No. 83 2009 Seq ID No. 84

O 2008/047241 A

(57) Abstract: The present invention relates to compounds comprising modified corticotrophin releasing factor peptide and specifically virocortin and virocortin-related peptides, modified derivatives thereof, and conjugates of such modified peptides and derivatives to serum components, preferably serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group, which is covalently attached to a modified peptide or derivative, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide or derivative to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention preferably exhibit a longer *in vivo* circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and preferably exhibit increased biological activity compared to the unconjugated peptides. The present invention also provides methods for the treatment and prevention of a disease or disorder comprising the administration of one or more of the compounds or conjugates of the invention to a subject in need of such treatment or prevention.

(88) Date of publication of the international search report: 22 April 2010

International application No. PCT/IB2007/004156

#### A. CLASSIFICATION OF SUBJECT MATTER

IPC: *C07K* 14/575 (2006.01), *A61K* 47/48 (2006.01), *A61K* 9/08 (2006.01), *A61P* 21/06 (2006.01), *A61P* 25/00 (2006.01), *A61P* 3/04 (2006.01) (more IPCs on the last page)

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K 14/575 (2006.01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used) Delphion, Pubmed, Scopus, Canadian Patent Database

Keywords: Urocortin, stresscopin, stresscopin-related peptide, "maleimido coupling with serum albumin to increase half-life"

#### C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
Y	WO 2005/012346 A1 (Bridon DP et al.) February 10, 2005 whole document	1-83				
Y	Jette L. et al. Human growth hormone-releasing factor (hGRF) <sub>1-29</sub> albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005, Vol. 146(7), pages 3050-3058, ISSN: 0952-5041 whole document	1-83				
Y	Hsu SY and Hsueh AJW. Human stresscopin and stresscopin-related peptides are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nature Medicine. 2001, Vol. 7 (5), pages 605-611, ISSN: 1078-8956 whole document	1-83				
Y	Asakawa A et al. Urocortin reduces food intake and gastric emptying in lean <i>ob/ob</i> obese mice. Gastroenterology. 1999, Vol. 116(6), pages 1287-1292, ISSN: 0016-5085 whole document	1-83				
[X] Further documents are listed in the continuation of Box C. [X] See patent family annex.						

whole document	
[X] Further documents are listed in the continuation of Box C	. [X] See patent family annex.
* Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier application or patent but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  "&" document member of the same patent family
Date of the actual completion of the international search  10 March 2009 (10-03-2009)	Date of mailing of the international search report  14 April 2009 (14-04-2009)
Name and mailing address of the ISA/CA Canadian Intellectual Property Office Place du Portage I, C114 - 1st Floor, Box PCT 50 Victoria Street Gatineau, Quebec K1A 0C9 Facsimile No.: 001-819-953-2476	Authorized officer  Ravinder Sardana 819- 997-4065

International application No. PCT/IB2007/004156

International application No. PCT/IB2007/004156

# Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

Thi			ernational search report has not been established in respect of certain claims under Article 17(2)(a) for the following			
1.	[3	<b>X</b> ]	Claim Nos.: 35, 36, 38-63 and 76-83 because they relate to subject matter not required to be searched by this Authority, namely:  Claims 35, 36, 38-63 and 76-83 encompass a method for treatment of the human or animal body by surgery or therapy, are not required to be searched nor is a written opinion required by this Authority (Rule 39.1 (iv) of the PCT). Regardless, this Authority has established a search report based on the alleged effect of the claimed subject matter defined in claims 35, 36, 38-63 and 76-			
2.	]	]	Claim Nos. : because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :			
3.	[	]	Claim Nos. : because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box	N	o <b>.</b> .	III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)			
1.	[	]	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.			
2.	[	]	As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.			
3.	[	]	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :			
4.	]	]	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. :			
			Remark on Protest  [ ] The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.  [ ] The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.  [ ] No protest accompanied the payment of additional search fees.			

International application No. PCT/IB2007/004156

A61P 9/00 (2006.01), A61P 9/02 (2006.01), C07K 1/107 (2006.01), C07K 19/00 (2006.01), C07K 14/765 (2006.01)						

Information on patent family members

International application No. PCT/IB2007/004156

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO 2005012346A1	10-02-2005	AU 2004261319A1 BR PI0412252A CA 2526957A1 CN 1964989A EP 1648933A1 EP 1648933A4 JP 2007520441T NO 20060888A US 2006241019A1	10-02-2005 19-09-2006 10-02-2005 16-05-2007 26-04-2006 28-02-2007 26-07-2007 25-04-2006 26-10-2006
US 6838274B2	04-01-2005	AT 408622T AU 8468301A AU 2001284683B2 CA 2418144A1 CN 1484650A DE 60135850D1 DK 130533473 EP 1305334A1 EP 1305334A1 EP 1305334B1 IL 154102D0 JP 2004505640T NZ 523803A RU 2278871C2 RU 2003105897A US 7223846B2 US 2002127221A1 US 2005191650A1 US 2007191592A1 WO 0212307A1	15-10-2008 18-02-2002 27-04-2006 14-02-2002 24-03-2004 30-10-2008 02-02-2009 02-05-2003 23-03-2005 17-09-2008 31-07-2003 26-02-2004 27-08-2004 27-06-2006 20-01-2005 29-05-2007 12-09-2002 01-09-2005 16-08-2007 14-02-2002